Clinical Fine Needle Aspiration Cytology and Core Biopsy in Symptomatic Patients with Normal Breast Radiological Imaging
Association of Breast Surgery ePoster Library. Rashid S. 05/15/17; 166279; P008
Sabina Rashid
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: Free hand clinical biopsy (FHCB) and FNA aims to avoid missing radiologically occult breast cancers but is associated with laboratory processing. The aim was to assess the diagnostic performance of clinical FHCB/FNA for patients presenting with a palpable abnormality and normal imaging.
Methods: A retrospective review of FHCB/FNA outcomes in symptomatic patients with palpable abnormality and normal or benign imaging at a single Institution (January 2015 – May 2016).
Results: In total, 81 patients (mean age=47.2 years, StD=14.6) underwent FHCB or FNA of which 77.8% had a pathological abnormality to account for clinical suspicion, and 6.2% had malignancy (Table 1). Of patients with normal or benign results, n=17 required further imaging and n=11 returned for clinical review, and the remainder were discharged following MDM discussion. 19 patients had second biopsies performed. No invasive disease was identified upon repeat biopsy, but 3 patients were found to have atypia.
The average amount paid in damages to individuals for delayed or failure to diagnose breast cancer is £60758.75 (NHS-LA data).Biopsy Result of patients %
diagnostic .0
breast tissue
changes .9
(atypia/ISLN) .9
/in-situ/B-cell lymphoma .2
The total laboratory costs of processing specimens was £46,200.
Conclusion: The majority of patients undergoing FHCB/FNAs were found to have normal or benign changes at substantial unit costs. However, a proportion of patients had disease that required further follow up or treatment after their initial FNA/biopsy. This demonstrates the potential for significant lesions (atypia or malignancy) to be missed or result in delayed diagnosis, and hence costs of processing need to be offset against litigation costs.
Methods: A retrospective review of FHCB/FNA outcomes in symptomatic patients with palpable abnormality and normal or benign imaging at a single Institution (January 2015 – May 2016).
Results: In total, 81 patients (mean age=47.2 years, StD=14.6) underwent FHCB or FNA of which 77.8% had a pathological abnormality to account for clinical suspicion, and 6.2% had malignancy (Table 1). Of patients with normal or benign results, n=17 required further imaging and n=11 returned for clinical review, and the remainder were discharged following MDM discussion. 19 patients had second biopsies performed. No invasive disease was identified upon repeat biopsy, but 3 patients were found to have atypia.
The average amount paid in damages to individuals for delayed or failure to diagnose breast cancer is £60758.75 (NHS-LA data).Biopsy Result of patients %
diagnostic .0
breast tissue
changes .9
(atypia/ISLN) .9
/in-situ/B-cell lymphoma .2
The total laboratory costs of processing specimens was £46,200.
Conclusion: The majority of patients undergoing FHCB/FNAs were found to have normal or benign changes at substantial unit costs. However, a proportion of patients had disease that required further follow up or treatment after their initial FNA/biopsy. This demonstrates the potential for significant lesions (atypia or malignancy) to be missed or result in delayed diagnosis, and hence costs of processing need to be offset against litigation costs.
Introduction: Free hand clinical biopsy (FHCB) and FNA aims to avoid missing radiologically occult breast cancers but is associated with laboratory processing. The aim was to assess the diagnostic performance of clinical FHCB/FNA for patients presenting with a palpable abnormality and normal imaging.
Methods: A retrospective review of FHCB/FNA outcomes in symptomatic patients with palpable abnormality and normal or benign imaging at a single Institution (January 2015 – May 2016).
Results: In total, 81 patients (mean age=47.2 years, StD=14.6) underwent FHCB or FNA of which 77.8% had a pathological abnormality to account for clinical suspicion, and 6.2% had malignancy (Table 1). Of patients with normal or benign results, n=17 required further imaging and n=11 returned for clinical review, and the remainder were discharged following MDM discussion. 19 patients had second biopsies performed. No invasive disease was identified upon repeat biopsy, but 3 patients were found to have atypia.
The average amount paid in damages to individuals for delayed or failure to diagnose breast cancer is £60758.75 (NHS-LA data).Biopsy Result of patients %
diagnostic .0
breast tissue
changes .9
(atypia/ISLN) .9
/in-situ/B-cell lymphoma .2
The total laboratory costs of processing specimens was £46,200.
Conclusion: The majority of patients undergoing FHCB/FNAs were found to have normal or benign changes at substantial unit costs. However, a proportion of patients had disease that required further follow up or treatment after their initial FNA/biopsy. This demonstrates the potential for significant lesions (atypia or malignancy) to be missed or result in delayed diagnosis, and hence costs of processing need to be offset against litigation costs.
Methods: A retrospective review of FHCB/FNA outcomes in symptomatic patients with palpable abnormality and normal or benign imaging at a single Institution (January 2015 – May 2016).
Results: In total, 81 patients (mean age=47.2 years, StD=14.6) underwent FHCB or FNA of which 77.8% had a pathological abnormality to account for clinical suspicion, and 6.2% had malignancy (Table 1). Of patients with normal or benign results, n=17 required further imaging and n=11 returned for clinical review, and the remainder were discharged following MDM discussion. 19 patients had second biopsies performed. No invasive disease was identified upon repeat biopsy, but 3 patients were found to have atypia.
The average amount paid in damages to individuals for delayed or failure to diagnose breast cancer is £60758.75 (NHS-LA data).Biopsy Result of patients %
diagnostic .0
breast tissue
changes .9
(atypia/ISLN) .9
/in-situ/B-cell lymphoma .2
The total laboratory costs of processing specimens was £46,200.
Conclusion: The majority of patients undergoing FHCB/FNAs were found to have normal or benign changes at substantial unit costs. However, a proportion of patients had disease that required further follow up or treatment after their initial FNA/biopsy. This demonstrates the potential for significant lesions (atypia or malignancy) to be missed or result in delayed diagnosis, and hence costs of processing need to be offset against litigation costs.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}